EJCTS Click here to locate an Ethicon representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofmann, H.S.
Right arrow Articles by Silber, R.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofmann, H.S.
Right arrow Articles by Silber, R.E.
Related Collections
Right arrow Lung - cancer

Eur J Cardiothorac Surg 2002;21:606-610
© 2002 Elsevier Science NL

Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer

H.S. Hofmanna*, C. Taegeb, C. Lautenschlägerc, H. Neefa, R.E. Silbera

a Department of Cardio-Thoracic Surgery, Martin Luther University, E.-Grube Straße 40, 06097 Halle, Germany
b Institute of Pathology, Martin Luther University, Halle-Wittenberg, Halle, Germany
c Institute of Medical Statistics, Martin Luther University, Halle-Wittenberg, Halle, Germany

Received 20 August 2001; received in revised form 3 January 2002; accepted 4 January 2002.

* Corresponding author. Tel.: +49-345-557-2719; fax: +49-345-557-2782
e-mail: stefan.hofmann{at}medizin.uni-halle.de

Objectives: This retrospective study evaluates the probability of survival in patients who had undergone resection for non-small cell lung cancer (NSCLC) and in whom residual disease at the resection margins was found. Methods: During a period of 6 years, 596 patients with NSCLC were operated upon with curative intention. Residual disease at the resection margin was divided into microscopic (R1) and macroscopic (R2). Results: Twenty-six patients (4.4%) showed R1 and 12 (2%) R2 residual disease. An extrabronchial (thoracic wall, vessels) R1 situation was found in five patients and a bronchial R1 infiltration in 21 cases. The bronchial resection margin was subject to peribronchial infiltration in most cases (16/21). A total of 17/21 (65%) patients with bronchial infiltration had N2 disease. Thirty day lethality was 3.8% in the R1 group. Fifteen patients had postoperative irradiation. The 5-year survival rate for patients with R1 resection was 14%. The differences in survival between patients with extrabronchial vs. bronchial infiltration and N0/N1 vs. N2 were significant using univariate analysis. Adjuvant radiation did not result (especially in N2 disease) in a survival benefit. Among 12 patients with macroscopic residual disease (R2), 3/12 (25%) died within the first 30 days after the operation, and none of the R2 patients survived the first year after the operation. Conclusions: Patients with an R1 situation have a survival rate of 14% comparable to curative resected patients (RO) in stage III. Adjuvant radiation had no clear effect on survival. Patients with macroscopic tumor (R2) should receive palliative treatment after the operation depending on their condition.

Key Words: Non-small cell lung cancer • Residual disease • Survival




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Wind, E. J. Smit, S. Senan, and J.-P. Eerenberg
Residual disease at the bronchial stump after curative resection for lung cancer
Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 29 - 34.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
G. P. Flake, M. P. Rivera, W. K. Funkhouser, S. J. Maygarden, K. L. Meadows, E. H. Long, P. S. Stockton, T. C. Jones, H. W. Yim, R. J.C. Slebos, et al.
Detection of Pre-Invasive Lung Cancer: Technical Aspects of the LIFE Project
Toxicol Pathol, January 1, 2007; 35(1): 65 - 74.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
S. Balasubramanian, J. Au, and J. Dunning
Should lobectomy patients with microscopic involvement of the bronchial resection margin undergo re-operation to improve their long-term survival?
Interactive CardioVascular and Thoracic Surgery, December 1, 2005; 4(6): 531 - 537.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Guo, M. G. House, C. Hooker, Y. Han, E. Heath, E. Gabrielson, S. C. Yang, S. B. Baylin, J. G. Herman, and M. V. Brock
Promoter Hypermethylation of Resected Bronchial Margins: A Field Defect of Changes?
Clin. Cancer Res., August 1, 2004; 10(15): 5131 - 5136.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. E.B. Swinson, J. L. Jones, D. Richardson, C. Wykoff, H. Turley, J. Pastorek, N. Taub, A. L. Harris, and K. J. O'Byrne
Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2003; 21(3): 473 - 482.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.